Literature DB >> 16382379

Plasma levels of NT-pro-BNP in patients with atrial fibrillation before and after electrical cardioversion.

D-I Shin1, K Jaekel, Ph Schley, A Sause, M Müller, R Fueth, T Scheffold, H Guelker, M Horlitz.   

Abstract

OBJECTIVE: Plasma levels of brain natriuretic peptide (BNP) have been examined in studies on patients with persistent atrial fibrillation, both before and after electrical cardioversion. Studied patients often showed a comorbidity with congestive heart failure, which complicates interpretation of measured BNP values as a natriuretic peptide. The aim of this study was to examine plasma levels of N-terminal fragment pro-brain natriuretic peptide (NT-pro-BNP), which is the more stable but inactive cleavage product of pro-BNP in patients with atrial fibrillation, but normal left ventricular ejection fraction, before and after electrical cardioversion. PATIENTS AND METHODS: NT-pro-BNP plasma levels of 34 consecutive patients were measured before, shortly after and 11 days after electrical cardioversion. All patients showed a normal ejection fraction after echocardiographic or laevocardiographic criteria.
RESULTS: At baseline, all patients showed elevated NT-pro-BNP compared to a healthy control group (1086 vs. 66.9 pg/ml, p<0.001). After a mean follow-up time of 11 days in patients with persistent restored sinusrhythm, NT-pro-BNP decreased from 1071 pg/ml at baseline to 300 pg/ml (p<0.001). In contrast, patients with recurrence of atrial fibrillation showed increased levels from 1570.5 pg/ml at baseline to 1991 pg/ml (p=0.13; n.s.). Recurrence of atrial fibrillation was independent from height of NT-pro-BNP levels at baseline (p=0.23).
CONCLUSIONS: Atrial fibrillation in patients with a normal left ventricular ejection fraction is associated with elevated NT-pro-BNP plasma levels, which decrease when a persistent sinus-rhythm can be restored by electrical cardioversion. On the other hand, NT-pro-BNP seems to increase (n.s.) when recurrence of atrial fibrillation occurs. Finally, NT-pro-BNP is no valid predictor for long-term success of sinus-rhythm restoration by electrical cardioversion.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16382379     DOI: 10.1007/s00392-005-0301-7

Source DB:  PubMed          Journal:  Z Kardiol        ISSN: 0300-5860


  20 in total

1.  New insights into the cardiac natriuretic peptides.

Authors:  R O Bonow
Journal:  Circulation       Date:  1996-06-01       Impact factor: 29.690

2.  Utility of B-natriuretic peptide in detecting diastolic dysfunction: comparison with Doppler velocity recordings.

Authors:  Emily Lubien; Anthony DeMaria; Padma Krishnaswamy; Paul Clopton; Jen Koon; Radmila Kazanegra; Nancy Gardetto; Erin Wanner; Alan S Maisel
Journal:  Circulation       Date:  2002-02-05       Impact factor: 29.690

3.  Impaired left atrial mechanical function after cardioversion: relation to the duration of atrial fibrillation.

Authors:  W J Manning; D I Silverman; S E Katz; M F Riley; P C Come; R M Doherty; J T Munson; P S Douglas
Journal:  J Am Coll Cardiol       Date:  1994-06       Impact factor: 24.094

Review 4.  Measurement of cardiac natriuretic hormones (atrial natriuretic peptide, brain natriuretic peptide, and related peptides) in clinical practice: the need for a new generation of immunoassay methods.

Authors:  A Clerico; S Del Ry; D Giannessi
Journal:  Clin Chem       Date:  2000-10       Impact factor: 8.327

5.  Brain natriuretic peptide predicts successful cardioversion in patients with atrial fibrillation and maintenance of sinus rhythm.

Authors:  Luís Beck-da-Silva; Adolfo de Bold; Margaret Fraser; Kathryn Williams; Haissam Haddad
Journal:  Can J Cardiol       Date:  2004-10       Impact factor: 5.223

6.  Discordant atrial natriuretic peptide and brain natriuretic peptide levels in lone atrial fibrillation.

Authors:  Patrick T Ellinor; Adrian F Low; Kristen K Patton; Marisa A Shea; Calum A Macrae
Journal:  J Am Coll Cardiol       Date:  2005-01-04       Impact factor: 24.094

7.  Effect of sinus rhythm restoration on plasma brain natriuretic peptide in patients with atrial fibrillation.

Authors:  Beata Wozakowska-Kapłon
Journal:  Am J Cardiol       Date:  2004-06-15       Impact factor: 2.778

8.  Brain natriuretic peptide levels fall rapidly after cardioversion of atrial fibrillation to sinus rhythm.

Authors:  Craig S Vinch; Jason Rashkin; Giridhar Logsetty; Dennis A Tighe; Jeffrey C Hill; Theo E Meyer; Lawrence S Rosenthal; Gerard P Aurigemma
Journal:  Cardiology       Date:  2004-09-22       Impact factor: 1.869

9.  Plasma proatrial natriuretic factor is predictive of clinical status in patients with congestive heart failure.

Authors:  K Dickstein; A I Larsen; V Bonarjee; M Thoresen; T Aarsland; C Hall
Journal:  Am J Cardiol       Date:  1995-10-01       Impact factor: 2.778

10.  Concomitant recovery of atrial mechanical and endocrine function after cardioversion in patients with persistent atrial fibrillation.

Authors:  Beata Wozakowska-Kapłon; Grzegorz Opolski
Journal:  J Am Coll Cardiol       Date:  2003-05-21       Impact factor: 24.094

View more
  17 in total

1.  NT-proBNP, but not ANP and C-reactive protein, is predictive of paroxysmal atrial fibrillation in patients undergoing pulmonary vein isolation.

Authors:  Jinqi Fan; Hua Cao; Li Su; Zhiyu Ling; Zengzhang Liu; Xianbin Lan; Yanping Xu; Weijie Chen; Yuehui Yin
Journal:  J Interv Card Electrophysiol       Date:  2011-09-21       Impact factor: 1.900

2.  Atrial fibrillation is an independent determinant of increased NT-proBNP levels in outpatients with signs and symptoms of heart failure.

Authors:  Borut Jug; Miran Sebestjen; Miso Sabovic; Maja Pohar; Irena Keber
Journal:  Wien Klin Wochenschr       Date:  2009       Impact factor: 1.704

3.  Level Of Natriuretic Peptide Determines Outcome In Atrial Fibrillation.

Authors:  Qi-Xian Zeng; Ming-Fen Wei; Wei Zhang; Yun Zhang; Jing-Quan Zhong
Journal:  J Atr Fibrillation       Date:  2010-01-01

4.  Factors associated with the development of atrial fibrillation in patients with rheumatic mitral stenosis.

Authors:  Mehmet Ozaydin; Yasin Turker; Ercan Varol; Sule Alaca; Dogan Erdogan; Nigar Yilmaz; Abdullah Dogan
Journal:  Int J Cardiovasc Imaging       Date:  2010-03-24       Impact factor: 2.357

5.  N-terminal pro-B-type natriuretic peptide variability in stable dialysis patients.

Authors:  Magid A Fahim; Andrew Hayen; Andrea R Horvath; Goce Dimeski; Amanda Coburn; David W Johnson; Carmel M Hawley; Scott B Campbell; Jonathan C Craig
Journal:  Clin J Am Soc Nephrol       Date:  2015-02-24       Impact factor: 8.237

6.  N-terminal pro-B-type natriuretic peptide is a major predictor of the development of atrial fibrillation: the Cardiovascular Health Study.

Authors:  Kristen K Patton; Patrick T Ellinor; Susan R Heckbert; Robert H Christenson; Christopher DeFilippi; John S Gottdiener; Richard A Kronmal
Journal:  Circulation       Date:  2009-10-19       Impact factor: 29.690

7.  Incremental predictive value of pre-procedural N-terminal pro-B-type natriuretic peptide for short-term recurrence in atrial fibrillation ablation.

Authors:  Hye Jin Hwang; Jung Woo Son; Byung-Ho Nam; Boyoung Joung; Byungho Lee; Jin-Bae Kim; Moon-Hyoung Lee; Yangsoo Jang; Namsik Chung; Won-Heum Shim; Seung-Yun Cho; Sung Soon Kim
Journal:  Clin Res Cardiol       Date:  2009-02-19       Impact factor: 5.460

8.  Determinants of plasma NT-pro-BNP levels in patients with atrial fibrillation and preserved left ventricular ejection fraction.

Authors:  Konstantinos P Letsas; Gerasimos S Filippatos; Loukas K Pappas; Constantinos C Mihas; Virginia Markou; Ioannis P Alexanian; Michalis Efremidis; Antonios Sideris; Alan S Maisel; Fotios Kardaras
Journal:  Clin Res Cardiol       Date:  2008-10-30       Impact factor: 5.460

9.  Natriuretic Peptides as Predictors of Atrial Fibrillation Recurrences Following Electrical Cardioversion.

Authors:  Theodoros A Zografos; Demosthenes G Katritsis
Journal:  Arrhythm Electrophysiol Rev       Date:  2013-11-29

Review 10.  Interpretation of B-type natriuretic peptide in cardiac disease and other comorbid conditions.

Authors:  Michael A Burke; William G Cotts
Journal:  Heart Fail Rev       Date:  2007-03-08       Impact factor: 4.654

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.